864082-33-7 Usage
General Description
2-Methyl-6-oxo-4-(4-(trifluoromethyl)phenyl)-1,4,5,6-tetrahydropyridine-3-carboxylic acid is a chemical compound with a complex structure. It belongs to the pyridine carboxylic acid family and is characterized by the presence of a tetrahydropyridine ring, a trifluoromethyl group, and a carboxylic acid functional group. 2-Methyl-6-oxo-4-(4-(trifluoromethyl)phenyl)-1,4,5,6-tetrahydropyridine-3-carboxylic acid may have potential pharmaceutical or industrial applications, as its structure suggests it could have biological activity or be used as a building block in chemical synthesis. It may also have properties that make it useful in the development of agrochemicals or materials science applications. Due to its complex and specialized nature, this compound would likely be of interest to researchers and professionals in the fields of chemistry, pharmacology, and material sciences.
Check Digit Verification of cas no
The CAS Registry Mumber 864082-33-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,0,8 and 2 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 864082-33:
(8*8)+(7*6)+(6*4)+(5*0)+(4*8)+(3*2)+(2*3)+(1*3)=177
177 % 10 = 7
So 864082-33-7 is a valid CAS Registry Number.
864082-33-7Relevant articles and documents
Development of dihydropyridone indazole amides as selective rho-kinase inhibitors
Goodman, Krista B.,Cui, Haifeng,Dowdell, Sarah E.,Gaitanopoulos, Dimitri E.,Ivy, Robert L.,Sehon, Clark A.,Stavenger, Robert A.,Wang, Gren Z.,Viet, Andrew Q.,Xu, Weiwei,Ye, Guosen,Semus, Simon F.,Evans, Christopher,Fries, Harvey E.,Jolivette, Larry J.,Kirkpatrick, Robert B.,Dul, Edward,Khandekar, Sanjay S.,Yi, Tracey,Jung, David K.,Wright, Lois L.,Smith, Gary K.,Behm, David J.,Bentley, Ross,Doe, Christopher P.,Hu, Erding,Lee, Dennis
, p. 6 - 9 (2007/10/03)
Rho kinase (ROCK1) mediates vascular smooth muscle contraction and is a potential target for the treatment of hypertension and related disorders. Indazole amide 3 was identified as a potent and selective ROCK1 inhibitor but possessed poor oral bioavailabi
